# Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers

> **NCT05749549** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Blueray Biopharma Co., Ltd.** · enrollment: 191 (estimated)

## Conditions studied

- Advanced Cancer
- Follicular Lymphoma
- Peripheral T Cell Lymphoma
- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** BR1733

## Key facts

- **NCT ID:** NCT05749549
- **Lead sponsor:** Shanghai Blueray Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2025-05
- **Final completion:** 2026-05
- **Target enrollment:** 191 (ESTIMATED)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05749549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05749549, "Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05749549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*